Longwood Healthcare Leaders 春季會議以麻省理工學院Koch研究所為中心，通過網絡會議邀請生物制藥公司的首席執行官、研發負責人、及頂級學術研究人員參加，共同商討，促進藥物研發的轉化，造福病人！會議由諾貝爾獎獲得者，Biogen/Alnylam 聯合創始人 Phil Sharp 共同主持。會議僅限受邀參加。

Longwood Healthcare Leaders Spring Meeting centered on MIT’s Koch Institute via web-conference with leading bio-pharma CEOs, heads of R&D, top academic researchers, and healthcare investors, co-hosted by Nobel laureate and Biogen/Alnylam co-founder Phil Sharp. Longwood Healthcare Leaders Meetings drive transparency and collaboration in order to accelerate the translation of discoveries into medicines to help patients. Meetings are invitation-only.

美迪西創始人兼CEO陳春麟博士將參加此次大會，并在5月4日上午 9:50 （美東時間）與 Raj Devraj (Rectify Pharmaceuticals公司CEO), Bill Hinshaw (Axcella Therapeutics 公司CEO),  Peter Lebowitz (Janssen 全球腫瘤治療領域負責人), Reenie McCarthy (Stealth BioTherapeutics 公司CEO)， Chen Schor (Adicet Bio 公司CEO)一起進行嘉賓討論，主題為“Expediting Research for Treatment and Cures”。

Dr. Chun-Lin Chen, founder & CEO of Medicilon, will participate in the panel discussion titled "Expediting Research for Treatment and Cures" on May 4 at 9:50 am ET. The other invited participants are Raj Devraj (CEO, Rectify Pharmaceuticals), Bill Hinshaw (CEO, Axcella Therapeutics), Peter Lebowitz (Global Oncology Therapeutic Area Head, Janssen), and Reenie McCarthy (CEO, Stealth BioTherapeutics). The panel discussion is moderated by Chen Schor (CEO, Adicet Bio).

陳春麟博士、美國商務發展副總裁 Stephen Grant及美國商務團隊將于 5 月 5 日下午 5:00-7:00（美東時間）參加 Garden Party。屆時將與參會的眾嘉賓進行詳細交談，共同探討我們的專業服務如何更快地加速各企業的藥物研發過程！

Dr. Chun-Lin Chen and Medicilon VP of US Business Development Dr. Stephen Grant together with our US Business Development team will be joining the Garden Party on MAY 5 at 5:00-7:00 pm ET. We are looking forward to meeting you in this party to discuss how our services and capabilities would support your research needs and expedite your drug discovery and development programs. Wish you a safe trip!

美迪西是一家專業的生物醫藥臨床前綜合研發服務CRO，為全球的醫藥企業和科研機構提供全方位的符合國內及國際申報標準的一站式新藥研發服務。我們關注全球醫藥行業創新發展的需求，立足于創新藥物研發的關鍵環節，憑借服務國內外生物醫藥行業所積累的經驗，構建涵蓋藥物發現、藥學研究以及臨床前研究關鍵技術的綜合性技術平臺，為全球生物醫藥行業提供全方位新藥臨床前研發服務。至2021年報告期末，美迪西已為全球超過1460家客戶提供新藥研發服務，參與研發完成的新藥項目有221件IND獲批臨床，與國內外優質客戶共同成長。美迪西將繼續立足全球視野，聚力中國創新，為人類健康貢獻力量！

Medicilon is an integrated contract research organization (CRO), providing comprehensive one-step new drug R&D for pharmaceutical enterprises and scientific research institutions around the world. With our experience in serving domestic and foreign biomedical industries, we have built an integrated technical platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, in a bid to provide comprehensive preclinical new drug R&D for the global biomedical industry.

18⁺

18⁺ years of experience in new drug R&D
18⁺年新藥研發經驗

1460⁺

Active clients worldwide
全球范圍內活躍客戶

2440⁺

Newdrug discovery scientists and service personnel新藥研發科學家及研發服務人員

74000⁺

Square meters of Laboratory floor space
研發實驗室

221

Projects successfully approved with NMPA, FDA, EMA, and TGA
221件IND在 NMPA、FDA、EMA 和 TGA 成功獲批

聯系我們：

郵箱：marketing@medicilon.com.cn

電話: +86 (21) 5859-1500（總機）